Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer

Fig. 1

MEDI3039 induces apoptotic cell death in basal B TNBC MB231 cells. a MEDI3039-induced caspase activation (left) and cell death (right) in MB231 cells. MEDI3039 was at least two orders of magnitude more potent compared with GST-TRAIL. MB231 cells were treated with drugs for 1 h for caspase assays and 72 h for MTS assays. Data is shown as average ± SEM of multiple independent experiments. EC50 and IC50 were obtained by GraphPad Prism Nonlinear regression analysis. b Z-VAD-FMK, a pan caspase inhibitor, completely blocked caspase-3/7 activation (left) and cell killing effect (right) of MEDI3039. Cells were pretreated with Z-VAD-FMK for 60 min before treated with MEDI3039. Data is shown as average ± SEM of multiple independent experiments. ****p < 0.0001, two-way ANOVA. c Z-VAD-FMK completely blocked caspase-3/7 activation (left) and cell killing effect (right) of GST-TRAIL. Data is shown as average ± SEM of multiple independent experiments. ***p < 0.001, ****p < 0.0001, two-way ANOVA

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us